BCL2 and cholangiocarcinoma: Since THZ1 could significantly repress the transcriptional expression of MCL1 without influencing the expression of BCL2 or BCL-XL in CCA, we hypothesized that it could act as a MCL1 inhibitor and synergize with ABT-263.